essenti
oil
eo
mixtur
volatil
compound
mainli
sesquiterpenoid
phenylpropanoid
etc
contain
hundr
individu
chemic
constitu
may
biolog
activ
secret
special
cell
secret
duct
caviti
glandular
hair
extract
distil
press
enfleurag
solvent
supercrit
fluid
gener
ga
spectrometri
use
determin
chemic
composit
eo
well
known
eo
composit
influenc
mani
factor
eg
environment
condit
soil
type
plant
part
chemotyp
plant
speci
isol
process
determin
biolog
activ
spread
multidrug
resist
bacteria
grow
antibiot
resist
mani
research
group
focus
research
programm
investig
antimicrobi
activ
plant
extract
hope
discov
new
antibiot
therefor
number
public
vitro
antimicrobi
activ
eo
dramat
increas
case
without
innov
previous
demonstr
oxygen
terpenoid
eo
eg
alcohol
aldehyd
ester
keton
peroxid
phenol
respons
strong
antimicrobi
activ
influenc
bacteri
vitro
studi
antimicrobi
activ
eo
describ
wide
rang
assay
eg
disc
diffus
agar
diffus
broth
dilut
etc
differ
paramet
bacteri
fungal
strain
agar
recip
incub
time
solvent
etc
thu
result
difficult
compar
case
reliabl
question
volatil
solubl
properti
eo
common
screen
method
eg
disc
diffus
agar
absorpt
appropri
antimicrobi
test
hood
et
compar
result
differ
method
use
determin
antimicrobi
activ
eo
author
conclud
disc
diffus
method
provid
true
result
water
solubl
compon
diffus
agar
medium
broth
dilut
method
mostli
accept
tween
concentr
use
enhanc
solubl
eo
must
taken
consider
may
increas
bacteri
growth
alter
cell
permeabl
tween
may
show
antagonist
synergist
effect
eo
result
lower
higher
antimicrobi
activ
therefor
highli
import
paramet
method
optim
investig
carri
produc
reproduc
antimicrobi
result
eo
accord
data
world
health
organ
lower
respiratori
tract
infect
lrti
respons
million
peopl
death
worldwid
regard
sex
number
femal
group
male
pneumonia
respons
caus
death
among
month
base
data
lrti
chronic
obstruct
pulmonari
diseas
copd
remain
top
major
killer
past
although
global
vaccin
action
plan
bacteria
virus
caus
rti
mani
peopl
suffer
influenza
pneumonia
tuberculosi
without
proper
treatment
diseas
kill
mani
peopl
worldwid
eo
may
possess
prevent
role
treatment
rti
applic
eo
via
inhal
seem
effect
way
cure
patient
volatil
natur
reach
site
intend
review
give
short
overview
infect
upper
lower
respiratori
tract
focus
frequent
develop
diseas
patient
among
vitro
method
vapour
phase
test
vpt
accept
detect
antimicrobi
activ
volatil
compound
airway
therefor
vpt
introduc
review
mode
antibacteri
action
eo
also
highlight
furthermor
articl
focus
recent
publish
vivo
studi
well
human
clinic
trial
recent
patent
concern
potenti
use
eo
volatil
constitu
treatment
rtd
also
describ
urti
includ
laryng
laryngotracheobronch
epiglott
pharyng
peritonsillar
abscess
rhiniti
although
urti
caus
virus
pathogen
eg
bacteria
also
involv
diseas
relev
bacteria
virus
caus
urti
summar
tabl
tabl
acut
laryng
almost
invari
caus
virus
usual
associ
influenza
common
cold
characterist
symptom
includ
hoars
deepen
voic
acut
laryngotracheobronch
croup
close
relat
laryng
rel
common
diseas
among
young
children
year
age
ill
associ
fever
inspiratori
stridor
hoars
harsh
bark
cough
infect
eg
parainfluenza
virus
affect
larynx
also
trachea
bronchi
croup
becom
seriou
infect
epiglotti
soft
tissu
vocal
cord
call
epiglott
symptom
includ
fever
difficulti
swallow
respiratori
obstruct
inspiratori
stridor
contrast
laryng
epiglott
usual
caus
bacteri
infect
mainli
haemophilu
influenza
type
main
symptom
pharyng
tonsil
character
erythemat
swollen
tissu
virus
bacteria
also
respons
infect
peritonsillar
abscess
common
children
older
year
young
adult
import
organ
infect
anaerob
eg
fusobacterium
necrophorum
treatment
peritonsillar
abscess
highli
import
spread
adjac
tissu
well
erod
carotid
arteri
caus
acut
rhiniti
common
cold
affect
children
adult
mainli
caus
virus
character
fever
increas
mucou
secret
sneez
wateri
trachea
bronchi
bronchiol
belong
lower
part
respiratori
system
import
diseas
acut
chronic
bronchiti
bronchiol
pneumonia
pathogen
lower
part
respiratori
tract
summar
tabl
tabl
acut
bronchiti
acut
inflamm
tracheobronchi
tree
accompani
cough
fever
often
clear
sputum
product
ill
persist
sputum
may
becom
purul
acut
bronchiti
mainli
caus
virus
case
bacteri
infect
respons
chronic
bronchiti
excess
mucu
product
lead
cough
sputum
day
least
consecut
month
success
patient
chronic
bronchiti
suffer
acut
infect
ill
mainli
caus
pathogen
bacteria
eg
h
influenza
streptococcu
pneumonia
moraxella
catarrhali
cigarett
smoke
inhal
fume
dust
also
relev
contribut
factor
bronchiol
inflamm
smaller
diamet
bronchiolar
epitheli
surfac
mainli
develop
first
year
life
characterist
symptom
includ
wheez
hyperinfl
cough
runni
nose
rapid
breath
respiratori
distress
respiratori
syncyti
viru
rsv
account
bronchiol
case
show
mark
season
winter
earli
spring
pneumonia
inflamm
lrt
involv
lung
support
tissu
danger
infect
easili
lead
patient
death
two
major
categori
pneumonia
pneumonia
pneumonia
associ
hospit
ventil
health
care
pathogenesi
pneumonia
complic
organ
caus
infect
mani
possibl
way
eg
upper
airway
colon
aspir
organ
pneumonia
mainli
caus
virus
eg
adenoviru
cytomegaloviru
parainfluenza
varicella
rubeola
rsv
primari
infect
virus
inhibit
host
defenc
mechan
lead
secondari
bacteri
infect
gener
fever
chill
chest
pain
cough
suggest
pneumonia
patient
complain
headach
nausea
vomit
abdomin
pain
diarrhoea
highlight
aetiolog
acut
pneumonia
strongli
depend
age
pneumonia
infant
children
caus
virus
wherea
less
pneumonia
adult
unfortun
pneumonia
lead
caus
death
among
hospit
pneumonia
occur
due
contamin
equip
use
inhal
therapi
moreov
patient
compromis
immun
system
much
higher
risk
tuberculosi
follow
tabl
tabl
repres
relev
bacteria
lead
pneumonia
mycobacterium
tuberculosi
often
aetiolog
agent
chronic
lower
respiratori
tract
case
fungi
eg
histoplasma
capsulatum
blastomyc
dermatitidi
cryptococcu
neoforman
also
caus
acut
pneumonia
incid
pneumonia
increas
among
older
patient
patient
chronic
obstruct
lung
diseas
diabet
impair
factor
eg
decreas
mucociliari
function
decreas
cough
reflex
may
contribut
greater
incid
pneumonia
cystic
fibrosi
cf
seriou
genet
diseas
lead
persist
bacteri
infect
lung
result
airway
cell
wall
damag
chronic
obstruct
lung
affect
children
adult
mucou
pseudomona
produc
larg
amount
extracellular
capsular
polysaccharid
isol
sputum
infect
patient
moreov
pathogen
eg
aureu
also
involv
pathogenesi
anis
oil
anisi
aetheroleum
obtain
steam
distil
dri
ripe
fruit
pimpinella
anisum
l
star
anis
oil
illicium
verum
hook
anis
oil
clear
colourless
pale
yellow
liquid
jellifi
fruit
contain
essenti
oil
major
compon
anis
oil
anisaldehyd
star
anis
anis
oil
use
treatment
respiratori
complaint
mainli
expector
cough
associ
singl
dose
anis
oil
three
time
daili
taken
two
week
use
children
adolesc
year
age
contraind
lack
data
presenc
estragol
person
known
sensit
anethol
avoid
anis
prepar
contain
eo
alcohol
extract
use
pregnanc
lactat
mild
oestrogen
activ
antifertil
effect
anethol
demonstr
allerg
reaction
affect
skin
respiratori
system
may
occur
frequenc
bitter
fennel
fruit
oil
foeniculi
amari
fructu
aetheroleum
obtain
steam
distil
ripe
fruit
foeniculum
vulgar
miller
ssp
vulgar
var
vulgar
eo
clear
colourless
pale
yellow
liquid
characterist
odour
main
constitu
oil
fenchon
tradit
herbal
medicin
product
bitter
fennel
fruit
oil
use
expector
cough
associ
cold
case
adult
elderli
eo
singl
dose
per
day
multipl
divid
dose
taken
two
week
use
children
adolesc
year
age
contraind
lack
data
presenc
estragol
hypersensit
activ
substanc
eg
may
develop
oestrogen
activ
excess
dose
fennel
oil
may
affect
hormon
therapi
oral
contracept
pill
hormon
replac
therapi
allerg
reaction
fennel
oil
affect
respiratori
system
may
occur
frequenc
eucalyptu
oil
eucalypti
aetheroleum
obtain
steam
distil
rectif
fresh
leav
fresh
termin
branchlet
variou
speci
eucalyptu
rich
frequent
use
speci
eucalyptu
globulu
labil
e
polybractea
rt
baker
e
smithii
rt
baker
oil
colourless
pale
yellow
liquid
aromat
camphorac
odour
pungent
camphorac
plant
essenti
oil
content
main
compon
less
minor
compon
includ
camphor
less
achiev
paramet
minim
less
desir
substanc
aldehyd
oil
obtain
initi
steam
distil
rectifi
alkalin
treatment
fraction
primari
use
eucalyptu
oil
includ
treatment
cough
cold
bronchiti
symptomat
relief
cold
catarrh
upper
respiratori
tract
inhal
drop
per
ml
boil
water
vv
solut
prepar
tablespoon
ml
per
litr
warm
water
appli
treatment
may
repeat
three
time
daili
eucalyptu
oil
use
ointment
contain
vm
oil
adult
children
year
thick
layer
three
time
eucalyptu
oil
prepar
appli
face
especi
nose
babi
littl
children
sinc
human
data
avail
eucalyptu
use
pregnanc
lactat
without
medic
peppermint
oil
mentha
piperita
aetheroleum
obtain
steam
distil
fresh
aerial
part
flower
plant
mentha
piperita
l
eo
colourless
pale
yellow
pale
liquid
characterist
odour
tast
follow
sensat
eo
yield
peppermint
contain
menthol
menthon
isomenthon
menthyl
acet
menthofuran
limonen
pulegon
carvon
higher
ratio
cineol
compar
therapeut
use
peppermint
oil
includ
symptomat
treatment
digest
disord
eg
flatul
irrit
bowel
syndrom
symptomat
treatment
cough
cold
drop
oil
ad
hot
water
appli
peppermint
oil
contraind
children
year
age
menthol
induc
reflex
apnoea
direct
applic
peppermint
oil
prepar
nasal
area
chest
infant
small
children
must
avoid
risk
laryng
bronchial
spasm
inhal
menthol
caus
apnoea
laryngoconstrict
suscept
individu
menthol
caus
jaundic
newborn
infant
due
dehydrogenas
defici
peppermint
oil
use
pregnanc
without
medic
advic
lack
evid
tea
tree
eo
melaleuca
aetheroleum
obtain
steam
distil
foliag
termin
branchlet
melaleuca
alternifolia
maiden
betch
cheel
linariifolia
smith
dissitiflora
f
mueller
andor
speci
melaleuca
clear
colourless
pale
yellow
liquid
characterist
plant
contain
approx
eo
major
compon
monoterpen
minimum
less
tea
tree
oil
use
treatment
respiratori
infect
eg
cold
influenza
bronchiti
extern
applic
liquid
prepar
contain
mm
tea
tree
oil
use
rare
contact
dermat
develop
pregnanc
tea
tree
oil
appli
data
connect
safe
thyme
oil
thymi
aetheroleum
obtain
steam
distil
fresh
flower
aerial
part
thymu
vulgari
l
zygi
loefl
ex
l
mixtur
speci
clear
yellow
dark
liquid
characterist
aromat
spici
odour
reminisc
dri
herbal
substanc
contain
eo
thyme
oil
contain
phenol
mainli
thymol
andor
carvacrol
therapeut
applic
thyme
oil
includ
respiratori
disord
bronchial
catarrh
support
treatment
pertussi
inhal
drop
thyme
oil
use
children
year
age
patient
epilepsi
diseas
thyroid
gland
pregnant
women
use
thyme
antimicrobi
activ
eo
vitro
extens
investig
demonstr
number
microorgan
gener
use
disc
diffus
agar
dilut
method
method
use
differ
paramet
eg
strain
microorgan
agar
recip
incub
time
etc
usual
without
innov
therefor
result
assay
difficult
compar
sometim
reliabl
question
forgotten
eo
solubl
substanc
thu
common
screen
method
disc
diffus
agar
absorpt
may
appropri
antimicrobi
test
eo
tradit
appli
respiratori
tract
infect
via
among
vitro
method
vapour
phase
test
vpt
demonstr
vapour
activ
eo
appropri
way
result
may
use
understand
antimicrobi
activ
respiratori
tract
vpt
gener
paper
disc
contain
eo
place
insid
surfac
upper
lid
lower
lid
contain
agar
suspens
test
microorgan
contain
approxim
cfuml
spread
surfac
plate
immedi
invert
top
lid
seal
parafilm
prevent
leakag
vapour
incub
inhibit
bacteri
growth
agar
plate
detect
measur
eo
activ
method
provid
rel
valu
author
defin
minimum
inhibitori
concentr
mic
atmospher
micair
appli
airtight
vapour
activ
eo
publish
first
maruzzella
et
today
invert
techniqu
use
sever
case
airtight
box
l
air
capac
appli
increas
vapour
concentr
review
publish
al
yousef
give
overview
test
method
invert
disc
volatil
vapour
agar
contact
airtight
box
divid
use
determin
antimicrobi
activ
eo
compon
gaseou
contact
method
moreov
factor
eg
volatil
evapor
speed
stabil
eo
exposur
time
chemic
composit
eo
incub
temperatur
growth
phase
locat
microorgan
test
concentr
eo
vp
affect
efficaci
vapour
activ
eo
also
discuss
base
review
eo
use
air
disinfect
healthcar
environ
control
rti
due
antibacteri
activ
observ
optim
vp
condit
unfortun
number
articl
respiratori
tract
pathogen
test
inouy
et
investig
eo
main
constitu
gaseou
state
h
influenza
pneumonia
pyogen
aureu
cinnamon
bark
lemongrass
thyme
oil
show
lowest
minim
inhibitori
dose
mid
mgl
air
follow
eo
contain
terpen
alcohol
eo
rich
keton
ether
hydrocarbon
high
mid
author
also
conclud
antibacteri
activ
eo
effect
high
vapour
concentr
short
exposur
time
h
influenza
sensit
strain
follow
pneumonia
pyogen
aureu
among
eo
main
constitu
cinnamaldehyd
thymol
show
highest
activ
mgl
air
follow
citral
perillaldehyd
octan
nonan
menthol
linalool
show
moder
activ
ester
geranyl
linalyl
acet
exhibit
weak
activ
aureu
mgl
air
anoth
studi
vapour
geranium
lemongrass
mixtur
bioscenttm
test
aureu
mrsa
enterococci
direct
contact
vapour
special
machin
st
protm
use
dispers
bioscenttm
environ
seal
box
environ
growth
mrsa
reduc
h
exposur
bioscenttm
vapour
offic
environ
eo
mixtur
produc
reduct
airborn
bacteria
h
result
suggest
geraniumlemongrass
oil
could
use
air
airborn
activ
eucalyptu
citriodora
eo
investig
alvarenga
et
studi
biochemometr
analyt
approach
involv
ccc
fraction
bioactiv
measur
chemometr
analysi
use
activ
measur
invert
techniqu
e
citriodora
eo
activ
compound
identifi
eg
citronellol
linalool
isopulegol
spatulenol
artifici
mixtur
amx
method
use
demonstr
interact
eo
compon
amx
contain
citronellol
citronel
eucalyptol
show
activ
citronel
major
constitu
e
citriodora
oil
weak
activ
author
highlight
potenti
addit
andor
synergist
effect
among
major
minor
phytoconstitu
rare
antivir
activ
eo
aerosol
vapour
investig
one
studi
antivir
effect
tea
tree
tto
eucalyptu
oil
euo
aerosol
rang
concentr
test
influenza
viru
aerosol
strong
antivir
activ
within
min
current
knowledg
mode
action
eo
pathogen
increas
mani
case
aureu
use
test
microorgan
one
studi
cellular
effect
inula
graveolen
santolina
corsica
eo
aureu
atcc
strain
effect
time
treatment
dose
cell
viabil
determin
bacteriolysi
assay
transmiss
electron
microscopi
use
observ
mark
structur
chang
caus
eo
treatment
author
suggest
cytoplasm
membran
cell
wall
involv
toxic
action
graveolen
corsica
eo
muthaiyan
et
investig
antimicrobi
effect
mode
action
terpeneless
cold
press
valencia
orang
cpvo
eo
mrsa
result
show
cpvo
oil
induc
cell
wall
stress
stimulu
consist
inhibit
cell
wall
synthesi
trigger
cell
lysi
observ
transmiss
electron
microscopi
sinc
eo
disrupt
cell
membran
structur
indirectli
affect
toxin
secret
differ
date
studi
demonstr
bacteri
cell
target
eo
includ
cell
wall
membran
therebi
disturb
atp
product
ph
homeostasi
moreov
eo
influenc
cellular
transcriptom
proteom
bacteria
resist
eo
bacteria
differ
cell
wall
structur
nazzaro
et
publish
review
mode
action
eo
pathogen
bacteria
conclud
eo
compon
singl
target
multipl
target
antimicrobi
activ
mention
previous
number
public
mechan
eo
bacteria
caus
rti
publish
studi
perform
bouhdid
et
activ
cinnamon
eo
ceo
contain
investig
p
aeruginosa
aureu
cell
membran
permeabl
p
aeruginosa
disturb
ceo
treatment
case
aureu
howev
flow
cytometr
analysi
reveal
presenc
ceo
aureu
enter
viabl
noncultur
state
state
virul
potenti
bacteria
preserv
cycl
infect
restart
bacteri
cell
recov
full
metabol
capac
fact
must
taken
consider
eo
activ
evalu
previous
workgroup
demonstr
effect
ceo
clove
eo
cleo
outer
membran
protein
omp
composit
p
oil
administ
cultur
concentr
x
mic
x
mic
incub
min
protein
disappear
treatment
ceo
cleo
decreas
amount
protein
may
explain
protein
synthesi
inhibit
effect
oil
receiv
similar
result
studi
publish
first
burt
et
mode
antimicrobi
action
eo
highli
relat
chemic
exampl
studi
aromadendren
main
compound
eucalyptu
globulu
oil
ego
show
higher
mic
valu
p
aeruginosa
aromadendren
cyclopropan
ring
caus
alkyl
protein
result
alter
furthermor
chemic
chang
eg
oxid
eo
compon
may
contribut
antibacteri
oxid
citral
air
alreadi
experienc
product
contribut
higher
antibacteri
eo
constitu
also
interact
transient
receptor
potenti
trp
ion
channel
locat
trp
superfamili
cation
channel
divid
six
subfamili
base
sequenc
homolog
includ
trpc
canon
trpv
vanilloid
trpm
melastatin
trpa
ankyrin
trpp
polycystin
trpml
mucolipin
ion
channel
thought
play
key
role
respiratori
diseas
asthma
chronic
obstruct
pulmonari
copd
cough
activ
divers
rang
chemic
eg
capsaicin
citral
agonist
menthol
agonist
allyl
isothiocyan
carvacrol
cinnamaldehyd
agonist
physic
stimuli
eg
temperatur
membran
potenti
chang
osmot
stress
investig
select
blocker
antagonist
channel
rapidli
grow
field
may
provid
attract
novel
strategi
treat
characterist
featur
respiratori
diseas
previous
demonstr
experiment
anim
patient
airway
diseas
mark
hypersensit
cough
induc
therefor
receptor
antagonist
propos
therapeut
receptor
inhal
decreas
evok
cough
guinea
pig
inhal
mixtur
significantli
reduc
cough
evok
citric
acid
healthi
review
chemic
biolog
properti
eg
cool
effect
toxic
menthol
review
publish
banner
et
summar
evid
modul
select
trp
channel
may
benefici
effect
target
key
featur
sever
respiratori
diseas
includ
inflamm
airway
airway
mucu
secret
cough
conclud
introduct
select
trp
channel
blocker
clinic
practic
may
open
excit
new
chapter
evalu
trp
channel
modul
therapeut
agent
despit
rapid
signific
advanc
understand
trp
channel
recent
year
import
gap
pharmacolog
physiolog
knowledg
great
number
constitu
eo
seem
sever
potenti
cellular
well
known
result
come
vivo
anim
model
directli
extrapol
human
may
provid
valuabl
data
mechan
constitu
test
full
clinic
applic
comprehens
vivo
studi
still
requir
part
result
recent
perform
anim
studi
deal
eo
action
respiratori
tract
diseas
summar
cf
sever
respiratori
tract
diseas
morbid
mortal
relat
lung
alter
character
viciou
circl
obstruct
infect
chronic
inflamm
bronchial
infect
induc
intens
inflammatori
process
character
massiv
invas
neutrophil
leucocyt
includ
eosinophil
lymphocyt
cf
patient
often
infect
aureu
h
influenza
p
recent
treatment
cf
studi
focu
applic
hyperton
salt
solut
osmot
agent
system
gsno
reductas
eo
may
play
role
treatment
cf
due
antimicrobi
effect
known
two
pathway
involv
mediat
effect
inhal
eo
constitu
neurolog
pathway
act
central
nervou
system
via
olfactori
pharmacolog
pathway
act
thought
effect
eo
due
ratio
constitu
may
differ
origin
ratio
eo
absorb
satou
et
studi
distribut
eo
compon
inhal
singl
mix
constitu
limonen
mice
inhal
min
level
constitu
measur
brain
liver
result
show
amount
brain
liver
twofold
greater
inhal
inhal
comparison
compon
mix
inhal
ratio
increas
three
time
vivo
investig
distribut
eo
constitu
may
contribut
understand
action
sever
studi
focu
effect
tea
tree
oil
tto
studi
action
inhal
tto
mice
investig
anim
receiv
zymosan
intraperiton
ip
elicit
periton
inflamm
submit
tto
inhal
inhal
min
periton
leukocyt
ptl
isol
count
level
reactiv
oxygen
speci
ro
cyclooxygenas
cox
activ
ptl
measur
result
demonstr
tto
inhal
exert
strong
influenc
immun
system
stimul
zymosan
inject
influenc
ptl
number
ro
level
cox
activ
mice
without
inflamm
axi
shown
mediat
effect
anoth
studi
properti
ocimum
micranthum
eo
omeo
rat
trachea
omeo
relax
contract
induc
kcl
carbachol
inhal
omeo
appli
aerosol
prevent
tracheal
hyperrespons
kcl
carbachol
anim
author
conclud
omeo
exert
peripher
analgesia
nocicept
inflammatori
origin
antispasmod
activ
rat
airway
effect
mainli
due
e
main
constitu
omeo
chines
studi
protect
effect
linalool
inflamm
investig
use
lipopolysaccharid
lp
raw
cell
vivo
lung
injuri
linalool
allevi
product
tumor
vitro
vivo
linalool
decreas
histopatholog
chang
lung
vivo
anoth
murin
model
action
lavend
eo
leo
experiment
induc
bronchial
asthma
studi
anim
balbc
mice
sensit
ip
inject
ovalbumin
ova
day
subsequ
challeng
nebul
ova
day
group
group
mice
inhal
eo
day
allerg
inflammatori
respons
determin
day
group
inhibit
airway
resist
observ
furthermor
lower
total
cell
number
eosinophil
cytokin
level
measur
bronchoalveolar
lavag
bal
fluid
peribronchi
perivascular
tissu
group
treat
leo
reduc
mrna
express
determin
lung
tissu
compar
group
addit
leo
treatment
decreas
mrna
express
lung
effect
mrna
express
signific
studi
leo
inhal
inhibit
allerg
inflamm
mucou
cell
hyperplasia
suppress
cytokin
mrna
therefor
eo
may
appli
treatment
bronchial
asthma
zhou
et
studi
effect
thymol
constitu
allerg
airway
inflamm
mous
asthma
model
anim
oral
treat
thymol
dose
mgkg
bodi
weight
h
ova
challeng
thymol
reduc
level
ige
well
number
inflammatori
cell
airway
moreov
thymol
decreas
airway
hyperrespons
block
activ
pathway
author
conclud
base
result
thymol
may
involv
treatment
allerg
anoth
experi
eo
isol
pistacia
integerrima
pi
test
inflamm
medicin
plant
tradit
use
india
eg
treatment
asthma
chronic
pieo
mgkg
administ
ip
four
day
anim
prior
lp
administr
dose
select
base
valu
preliminari
efficaci
studi
eo
treatment
reduc
increas
total
cell
count
neutrophil
count
total
protein
albumin
level
bal
fluid
myeloperoxidas
mpo
level
lung
homogen
histopatholog
chang
also
show
protect
effect
pieo
treatment
accord
find
pieo
may
role
treatment
bronchial
asthma
complex
mode
action
inhibitori
effect
level
macrophag
mpo
etc
case
new
techniqu
involv
investig
action
eo
nicolato
et
use
pharmacolog
magnet
reson
imag
examin
secretori
respons
induc
eo
scotch
pine
rosemari
peppermint
airway
surfac
fluid
scotch
pine
eo
inhal
significantli
increas
surfac
fluid
middl
portion
trachea
rosemari
eo
show
weaker
secretori
respons
secretori
respons
detect
peppermint
oil
inhal
techniqu
direct
effect
eo
airway
perform
tradit
chines
medicin
tcm
mosla
dianthera
aromat
herb
use
treatment
cough
cold
fever
bronchiti
nasal
congest
wu
et
studi
chemic
composit
dianthera
eo
mdeo
evalu
effect
mice
infect
influenza
viru
iva
anim
treat
mdeo
consecut
day
dose
mgkg
level
serum
antioxid
paramet
eg
malondialdehyd
mda
superoxid
dismutas
sod
total
antioxid
capac
taoc
glutathion
peroxidas
determin
lung
tissu
mdeo
elemicin
thymol
main
constitu
mdeo
signific
effect
decreas
lung
viral
titer
inhibit
pneumonia
reduc
level
serum
enhanc
antioxid
activ
lung
tissu
iva
infect
mice
author
conclud
mdeo
could
provid
safe
effect
therapeut
candid
treatment
influenza
subsequ
viral
acut
otiti
media
aom
one
common
viral
upper
respiratori
tract
infect
studi
effect
orang
peel
essenti
oil
opeo
microcapsul
oxid
injuri
evalu
mice
acut
otiti
media
three
group
anim
fed
diet
contain
opeo
microcapsul
daili
day
pharmacolog
find
show
opeo
treatment
could
decreas
serum
cochlea
malondialdehyd
mda
iga
igg
igm
level
increas
antioxid
enzym
activ
therefor
conclud
microcapsul
contain
opeo
could
decreas
oxid
injuri
aom
rat
mention
earlier
number
articl
focus
vitro
antimicrobi
activ
eo
massiv
increas
contrast
number
human
trial
increas
extent
vitro
studi
previous
individu
compon
extens
use
human
experi
follow
respiratori
activ
menthol
alreadi
prove
antituss
low
increas
sensat
nasal
airflow
give
impress
depress
ventil
respiratori
drive
compar
higher
reduc
respiratori
discomfort
sensat
action
eg
ciliari
transport
promot
lung
function
use
treat
divers
rang
respiratori
condit
comprehens
human
trial
demonstr
benefici
effect
variou
respiratori
condit
handbook
essenti
oil
edit
baser
accord
result
eucalyptu
eo
effect
appli
treatment
asthma
acut
chronic
bronchiti
copd
common
cold
sinus
howev
necessari
mention
eo
high
content
menthol
appli
face
infant
today
articl
focu
eo
eucalyptu
myrtacea
peppermint
lamiacea
eo
plant
famili
howev
number
human
trial
highlight
articl
investig
therapeut
applic
eo
rtd
abstract
publish
russian
chines
therefor
articl
give
inform
narrow
group
research
accord
case
report
old
femal
patient
affect
respiratori
syncyti
viru
rsv
treat
eo
mixtur
contain
lavandula
latifolia
thymu
mastichina
balsam
abi
mentha
x
three
drop
appli
fibrou
filter
insert
base
fan
diffus
mixtur
nebul
room
everi
six
hour
passiv
inhal
patient
oxygen
requir
decreas
litr
per
minut
within
hour
observ
studi
toler
ointment
adolesc
year
adult
suffer
upper
respiratori
tract
infect
cold
acut
chronic
bronchiti
bronchial
catarrh
hoars
patient
involv
studi
ointment
contain
eucalyptu
eo
eo
menthol
product
use
inunct
patient
inhal
inunct
inhal
respect
mean
applic
time
day
toler
rate
excel
good
physician
patient
patient
report
advers
drug
reaction
eg
hypersensit
skin
reaction
n
cough
n
obstruct
respiratori
tract
symptom
n
hypersensit
reaction
mucou
membran
n
accord
result
author
suggest
applic
ointment
urti
adolesc
panahi
et
investig
effect
herbal
product
lamigex
contain
eo
syzygium
aromaticum
lavandula
angustifolia
geranium
robertianum
treatment
acut
extern
otiti
aeo
compar
effect
ciprofloxacin
seventi
randomli
assign
patient
receiv
ciprofloxacin
lamigex
group
administ
three
drop
everi
hour
week
everi
case
cleans
ear
canal
treatment
patient
examin
specialist
aeo
symptom
moreov
ear
discharg
cultur
also
check
begin
well
end
trial
pain
sever
also
record
visual
analogu
scale
begin
third
seventh
day
studi
antibiot
lamigex
treatment
improv
patient
condit
reduc
pain
sever
howev
rate
pain
improv
differ
two
group
number
posit
cultur
also
reduc
ciprofloxacin
lamigex
treatment
end
necessari
highlight
undilut
eo
drip
ear
dilut
eo
may
place
cotton
wad
partial
smaller
randomli
assign
adult
suffer
common
cold
inhal
air
either
steam
mix
eucalyptu
eo
camphor
menthol
ww
hour
mean
concentr
eo
compound
inspir
air
inhal
group
spirometr
paramet
significantli
improv
measur
min
improv
hour
paramet
includ
forc
vital
capac
fvc
total
amount
air
forcibl
exhal
full
inspir
forc
expiratori
volum
one
second
amount
air
forcibl
exhal
one
second
forc
expiratori
volum
three
second
amount
air
forcibl
exhal
three
second
maximum
expiratori
flow
rate
mefr
maximum
forc
flow
rate
full
expir
forc
expiratori
flow
mean
forc
expiratori
flow
first
fvc
prospect
random
open
studi
includ
children
year
age
effect
nigella
sativa
eo
nseo
treatment
wheez
associ
lower
respiratori
tract
ill
control
group
n
administ
bronchodil
test
group
n
receiv
nseo
oral
dose
mlkg
bodi
weightday
divid
two
portion
everi
h
day
patient
examin
day
treatment
day
treatment
measur
pulmonari
index
pi
peak
expiratori
flow
rate
pefr
paramet
accord
find
nseo
significantli
reduc
pi
compar
control
group
day
improv
pefr
valu
test
group
control
group
differ
howev
author
prove
benefici
role
nseo
manag
wheez
associ
lower
respiratori
tract
ill
studi
involv
children
necessari
make
final
conclus
regard
safe
applic
eo
anoth
prospect
random
control
trial
activ
spray
contain
eo
eucalyptu
citriodora
e
globulu
mentha
x
piperita
origanum
syriacum
rosmarinu
officinali
studi
patient
patient
test
group
use
spray
time
day
spray
time
day
chang
debilit
symptom
sore
throat
hoars
cough
assess
patient
minut
use
spray
particip
test
group
report
greater
improv
symptom
compar
particip
control
group
differ
symptom
sever
two
group
day
treatment
base
result
author
suggest
local
rather
system
effect
spray
upper
respiratori
random
clinic
trial
efficaci
toler
fort
studi
acut
patient
includ
random
particip
receiv
mg
capsul
per
day
week
investig
evalu
patient
symptom
baselin
day
treatment
particip
record
intak
medic
wellb
symptom
diari
reduc
cough
period
therefor
patient
suffer
sleep
disturb
moreov
particip
toler
treatment
well
tradit
frequent
use
product
germani
treatment
rtd
mani
year
worth
mention
sever
human
studi
patient
symptom
measur
experi
without
microbiolog
investig
sinc
bacteri
cultur
check
begin
well
end
trial
show
infect
upper
lower
respiratori
tract
part
mani
kind
microorgan
respons
rtd
achiev
appropri
treatment
rtd
eg
administr
antibiot
medicin
inhal
eo
definit
import
diagnos
type
microbiolog
agent
caus
rtd
includ
rti
antimicrobi
potenc
eo
respiratori
tract
pathogen
well
known
age
antimicrobi
drug
often
high
price
side
effect
eo
rel
cheap
safe
natur
materi
applic
techniqu
substanc
variabl
depend
symptom
diseas
treat
area
commonli
use
method
inhal
divid
activ
passiv
techniqu
activ
inhal
mean
patient
use
inhal
devic
patch
directli
inhal
volatil
compon
eo
use
passiv
inhal
well
eo
appli
environ
via
heat
vapor
forc
air
cheapest
way
reliev
symptom
respiratori
diseas
vapour
inhal
bowl
hot
water
contain
small
amount
eucalyptu
oil
euo
inhal
could
effect
applic
towel
head
case
could
directli
inhal
concentr
aromat
last
year
sever
patent
appear
tri
develop
portabl
inhal
devic
suitabl
deliveri
system
eo
cheap
practic
small
pocket
inhal
use
euo
invent
treatment
respiratori
condit
simpl
devic
drop
eo
appli
fabric
materi
appropri
glass
vial
patient
inhal
vapour
directli
nostril
mouth
best
result
observ
inhal
last
minut
repeat
sever
time
similar
inhal
eas
nasal
congest
quell
cough
consist
paper
wrapper
around
fibrou
cylindr
plug
aromat
substanc
euo
menthol
along
centrelin
develop
toward
plug
airtight
aluminium
foil
guarante
devic
hermet
seal
aromat
substanc
remain
fresh
simpl
use
lower
price
compar
plastic
inhal
dispos
hygien
form
advantag
devic
patient
directli
inhal
eo
nose
lead
reduct
nasal
person
aromatherapi
devic
releas
volatil
substanc
flexibl
inner
contain
cover
rigid
outer
shell
flexibl
inner
part
contain
fibrou
materi
eg
cotton
satur
aromat
substanc
eg
eo
cap
close
inner
part
includ
flip
nozzl
oper
defin
posit
permit
releas
effect
aroma
patient
inhal
close
posit
nozzl
confirm
vapour
eo
escap
inhal
use
devic
easili
oper
one
hand
flexibl
contain
deliv
kind
aromat
substanc
exact
aromatherapi
patch
applic
anoth
possibl
solut
treat
prevent
respiratori
infect
case
use
special
carrier
also
import
keep
aromat
substanc
fresh
constant
form
limit
releas
inventor
presum
live
respiratori
tract
pathogen
inactiv
get
contact
inhal
vapour
henc
satur
patch
usual
place
vicin
nasal
pathway
applic
appropri
mask
also
patent
adhes
patch
contain
safe
effect
amount
eo
eg
wintergreen
cinnamon
ginger
peppermint
lemon
clove
clari
sage
chamomil
alon
combin
patch
uniqu
vehicl
adhes
viscoelast
natur
maintain
stabil
conveni
use
eo
patch
appli
patient
eo
could
continu
make
contact
skin
patient
volatil
compon
releas
case
inventor
appli
cyclodextrin
carri
activ
substanc
control
releas
volatil
anoth
patent
adhes
path
contain
uniqu
foramin
carrier
develop
carrier
adhes
bind
bodi
part
eg
face
neck
chest
releas
volatil
substanc
menthol
thymol
camphor
oil
peppermint
eucalyptu
ginger
easili
inhal
user
nose
mouth
benefit
foramin
structur
reduc
incid
allerg
anoth
patent
vail
w
b
vail
l
possibl
use
eo
treatment
sever
acut
respiratori
syndrom
author
recommend
inhal
eo
eucalyptu
globulu
e
citriodora
e
radiatto
melaleuca
alternifolia
reduc
risk
infect
public
place
durat
frequenc
inhal
precis
determin
interest
patent
summar
articl
written
sienkiewicz
et
final
encapsul
eo
constitu
appli
pharmaceut
technolog
decreas
volatil
stabil
compound
improv
product
prolong
biolog
sever
patent
book
chapter
karlsen
describ
encapsul
program
releas
techniqu
use
eo
absolut
agre
author
technic
solut
may
open
new
area
applic
eo
even
treatment
rtd
eo
interest
natur
product
possess
variou
biolog
properti
essenti
oil
may
contain
hundr
individu
chemic
compon
mainli
sesquiterpenoid
phenylpropanoid
therapeut
purpos
administ
via
inhal
eg
eucalyptu
oil
oral
eg
peppermint
oil
eg
rosemari
oil
oil
high
phenol
content
instanc
thyme
clove
antisept
properti
complex
effect
eg
antibacteri
antivir
mucolyt
bronchodil
etc
use
valuabl
materi
treatment
differ
respiratori
tract
diseas
eo
appli
exclus
base
upon
use
eo
use
base
upon
use
sever
vitro
techniqu
antimicrobi
activ
eo
test
today
vivo
anim
model
respiratori
tract
diseas
offer
good
possibl
test
divers
biolog
effect
howev
highlight
number
human
trial
still
low
furthermor
studi
sever
limit
firstli
small
sampl
size
may
limit
interpret
result
secondli
short
period
treatment
eg
day
suffici
interpret
result
well
anoth
limit
associ
safeti
use
eo
howev
case
investig
observ
sever
studi
design
order
conclud
safeti
applic
eo
formula
addit
difficult
perform
trial
includ
eo
individu
constitu
without
doubt
studi
princip
human
trial
need
assess
efficaci
toler
eo
respiratori
tract
diseas
trial
would
also
import
data
come
human
studi
may
provid
idea
develop
patent
might
open
novel
perspect
develop
product
well
